Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Revelation Biosciences, Inc. (REVB)
USD1.09
+0.05 (+4.81%)
US NASDAQ Healthcare Biotechnology
Address
4660 La Jolla Village Drive 92122
San Diego, CA, US
San Diego, CA, US
CEO
James Rolke
Website
revbiosciences.com
IPO
2020-11-17
CIK 1810560 ISIN US76135L8046
Also trades on
NASDAQ Capital Market · REVB (USD)
NASDAQ Capital Market · REVBU (USD)
NASDAQ Global Market · REVBW (USD)
Description
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Petra Acquisition, Inc. | PAICU | 2021-09-17 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.09
+0.05 (+4.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
61.9K
Beta
-0.12
Float Shares
2.76M
Free Float %
74.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.31% | +2.97% | -11.11% | -28.77% | -73.54% | -67.50% | -97.34% | -99.98% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
1.09
DCF (Unlevered)
15.14
+1,289.2%
DCF (Levered)
16.03
+1,371.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-5.01
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+72.7% ★ Q1'26: -28.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +3,385.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+262.0% Q1'26: +230.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08× Q1'26: -0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
48.97M
48.97M – 48.97M
|
2.28M
2.28M – 2.28M
-95.3% YoY
|
25.38M
25.38M – 25.38M
+1,011.3% YoY
|
54.61M
54.61M – 54.61M
+115.2% YoY
|
117.61M
117.61M – 117.61M
+115.4% YoY
|
| EBITDA |
-7.95M
|
-9.04M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-7.98M
|
-9.07M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-15.04M
est: -246.32M (+93.9%)
|
-8.91M
est: -22.72M (+60.8%)
|
-3.25M
-4.45M – -2.05M
+85.7% YoY
|
-2.24M
-2.88M – -1.60M
+31.0% YoY
|
577.3K
577.3K – 577.3K
+125.7% YoY
|
1.88M
1.88M – 1.88M
+225.8% YoY
|
3.68M
3.68M – 3.68M
+95.4% YoY
|
| SGA |
4.43M
|
5.01M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-87.68
est: -1,436.16 (+93.9%)
|
-23.95
est: -36.60 (+34.6%)
|
-5.24
-7.17 – -3.30
+85.7% YoY
|
-3.62
-4.64 – -2.57
+31.0% YoY
|
0.93
0.93 – 0.93
+125.7% YoY
|
3.03
3.03 – 3.03
+225.8% YoY
|
5.92
5.92 – 5.92
+95.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
2
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AXA IM Prime Impact GP S.à.r.l | 1.96M | 8.32% | — | 1.96M | — | — | FI, PN | Luxembourg | 2023-02-14 | ↗ |
| 2 | AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 1.96M | 8.32% | — | 1.96M | — | — | FI, PN | Luxembourg | 2023-02-14 | ↗ |
| 3 | AXA Investment Managers Paris S.A. | 1.96M | 8.32% | — | 1.96M | — | — | FI, IA | France | 2023-02-14 | ↗ |
| 4 | AXA Investment Managers S.A. | 1.96M | 8.32% | — | 1.96M | — | — | FI, HC | France | 2023-02-14 | ↗ |
| 5 | AXA Investment Managers UK Ltd. | 1.96M | 8.32% | — | 1.96M | — | — | FI, IA | United Kingdom | 2023-02-14 | ↗ |
| 6 | AXA S.A. | 1.96M | 8.32% | — | 1.96M | — | — | FI, HC | France | 2023-02-14 | ↗ |
| 7 | Investment Management | 877.4K | 11.03% | 777.4K | — | 877.4K | — | IA | York | 2021-08-10 | ↗ |
| 8 | Lawrence M. Feis | 865.6K | 10.83% | 865.6K | — | 865.6K | — | IN | Illinois | 2021-09-28 | ↗ |
| 9 | LP | 795.4K | 5.80% | — | 795.4K | — | 795.4K | IA, PN | Bermuda | 2022-01-20 | ↗ |
| 10 | WONG | 795.4K | 5.80% | — | 795.4K | — | 795.4K | HC, IN | Bermuda | 2022-01-20 | ↗ |
| 11 | LINDEN CAPITAL L.P. | 744.7K | 5.40% | — | 744.7K | — | 744.7K | PN | Bermuda | 2022-01-20 | ↗ |
| 12 | LLC | 744.7K | 5.40% | — | 744.7K | — | 744.7K | HC | Bermuda | 2022-01-20 | ↗ |
| 13 | Absolute Return Strategies LP | 700.0K | 8.00% | — | 700.0K | — | 700.0K | PN | Delaware | 2020-10-16 | ↗ |
| 14 | Fund Management, LLC | 700.0K | 8.00% | — | 700.0K | — | 700.0K | OO | Delaware | 2020-10-16 | ↗ |
| 15 | Glass | 700.0K | 8.00% | — | 700.0K | — | 700.0K | HC | Delaware | 2020-10-16 | ↗ |
| 16 | ANDREW M. WEISS, PH.D. | 488.3K | 5.37% | — | 488.3K | — | 488.3K | HC | USA | 2022-02-09 | ↗ |
| 17 | WAM GP LLC | 488.3K | 5.37% | — | 488.3K | — | 488.3K | HC | DELAWARE | 2022-02-09 | ↗ |
| 18 | WEISS ASSET MANAGEMENT LP | 488.3K | 5.37% | — | 488.3K | — | 488.3K | IA | DELAWARE | 2022-02-09 | ↗ |
| 19 | Jeff Easton | 186.5K | 5.20% | 186.5K | — | 186.5K | — | IN | Delaware | 2023-02-21 | ↗ |
| 20 | Lind Global Fund II LP | 186.5K | 5.20% | 186.5K | — | 186.5K | — | PN | Delaware | 2023-02-21 | ↗ |
| 21 | Lind Global Partners II LLC | 186.5K | 5.20% | 186.5K | — | 186.5K | — | OO | Delaware | 2023-02-21 | ↗ |
| 22 | Mitchell P. Kopin | 185.0K | 4.99% | — | 185.0K | — | 175.4K | HC, IN | Delaware | 2023-02-21 | ↗ |
| 23 | Glazer Capital, LLC | — | 0.00% | — | — | — | — | IA, OO | State of Delaware | 2022-02-14 | ↗ |
| 24 | Hudson Bay Capital Management LP | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-04 | ↗ |
| 25 | Meteora Capital, LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2022-08-17 | ↗ |
| 26 | Paul J. Glazer | — | 0.00% | — | — | — | — | IN | United States | 2022-02-14 | ↗ |
| 27 | Polar Asset Management Partners Inc. | — | 0.00% | — | — | — | — | IA | Canada | 2022-02-11 | ↗ |
| 28 | Sander Gerber | — | 0.00% | — | — | — | — | IN | Delaware | 2022-02-04 | ↗ |
| 29 | Vik Mittal | — | 0.00% | — | — | — | — | IN | Delaware | 2022-08-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
23.4K
Cash buys
—
Cash sales
—
Net activity
-23,400
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Zygmont Chester Stanley III | Officer | F-InKind | D | Common Stock | 13,285 | 1.10 | 14.6K | 92,063 | I | ↗ |
| 2026-04-30 | Rolke James | Director / Officer | F-InKind | D | Common Stock | 10,115 | 1.13 | 11.4K | 214,738 | D | ↗ |
| 2026-02-04 | Zygmont Chester Stanley III | Officer | F-InKind | D | Common Stock | 13,100 | 1.65 | 21.6K | 105,348 | I | ↗ |
| 2026-02-03 | Rolke James | Director / Officer | F-InKind | D | Common Stock | 8,521 | 1.86 | 15.8K | 224,853 | D | ↗ |
| 2026-02-03 | ROPER JESS | Director | F-InKind | D | Common Stock | 1,591 | 1.85 | 2.9K | 12,828 | D | ↗ |
| 2026-02-03 | Chawla Lakhmir S | Director | F-InKind | D | Common Stock | 2,261 | 1.85 | 4.2K | 12,158 | D | ↗ |
| 2026-02-03 | CARVER JENNIFER | Director | F-InKind | D | Common Stock | 1,661 | 1.87 | 3.1K | 12,758 | D | ↗ |
| 2026-01-08 | Zygmont Chester Stanley III | Officer | A-Award | A | Common Stock | 78,145 | 0.90 | 70.3K | 473,790 | I | ↗ |
| 2026-01-08 | Rolke James | Director / Officer | A-Award | A | Common Stock | 532,829 | 0.90 | 479.5K | 933,489 | D | ↗ |
| 2026-01-08 | ROPER JESS | Director | A-Award | A | Common Stock | 41,981 | 0.90 | 37.8K | 57,667 | D | ↗ |
| 2026-01-08 | Chawla Lakhmir S | Director | A-Award | A | Common Stock | 41,981 | 0.90 | 37.8K | 57,667 | D | ↗ |
| 2026-01-08 | CARVER JENNIFER | Director | A-Award | A | Common Stock | 41,981 | 0.90 | 37.8K | 57,669 | D | ↗ |
| 2025-10-29 | Zygmont Chester Stanley III | Officer | A-Award | A | Common Stock | 390,614 | 1.28 | 500.0K | 395,645 | I | ↗ |
| 2025-10-29 | Rolke James | Director / Officer | A-Award | A | Common Stock | 390,614 | 1.28 | 500.0K | 400,660 | D | ↗ |
| 2025-10-29 | ROPER JESS | Director | A-Award | A | Common Stock | 15,625 | 1.28 | 20.0K | 15,686 | D | ↗ |
| 2025-10-29 | Chawla Lakhmir S | Director | A-Award | A | Common Stock | 15,625 | 1.28 | 20.0K | 15,686 | D | ↗ |
| 2025-10-29 | CARVER JENNIFER | Director | A-Award | A | Common Stock | 15,625 | 1.28 | 20.0K | 15,688 | D | ↗ |
| 2025-02-11 | Zygmont Chester Stanley III | Officer | A-Award | A | Common Stock | 15,048 | 3.87 | 58.2K | 15,076 | I | ↗ |
| 2025-02-11 | TIDMARSH GEORGE F | Director | A-Award | A | Common Stock | 181 | 3.87 | 700.47 | 268 | I | ↗ |
| 2025-02-11 | Rolke James | Director / Officer | A-Award | A | Common Stock | 30,095 | 3.87 | 116.5K | 30,137 | D | ↗ |
| 2025-02-11 | ROPER JESS | Director | A-Award | A | Common Stock | 181 | 3.87 | 700.47 | 183 | D | ↗ |
| 2025-02-11 | Chawla Lakhmir S | Director | A-Award | A | Common Stock | 181 | 3.87 | 700.47 | 181 | D | ↗ |
| 2025-02-11 | CARVER JENNIFER | Director | A-Award | A | Common Stock | 181 | 3.87 | 700.47 | 187 | D | ↗ |
| 2023-12-08 | TIDMARSH GEORGE F | Director | S-Sale | D | Common Stock | 27,771 | 0.52 | 14.4K | 0 | — | ↗ |
| 2023-10-16 | TIDMARSH GEORGE F | Director | S-Sale | D | Common Stock | 1,845 | 0.65 | 1.2K | 27,771 | — | ↗ |
| 2023-09-28 | TIDMARSH GEORGE F | Director | S-Sale | D | Common Stock | 1,429 | 0.69 | 986.01 | 42,096 | — | ↗ |
| 2023-09-27 | Chawla Lakhmir S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-18 | TIDMARSH GEORGE F | Director | S-Sale | D | Common Stock | 4,000 | 0.74 | 3.0K | 39,348 | — | ↗ |
| 2023-09-15 | TIDMARSH GEORGE F | Director | S-Sale | D | Common Stock | 9,500 | 0.73 | 6.9K | 43,348 | — | ↗ |
| 2023-09-14 | TIDMARSH GEORGE F | Director | S-Sale | D | Common Stock | 12,000 | 0.75 | 9.0K | 52,848 | — | ↗ |
| 2023-04-18 | TIDMARSH GEORGE F | Director | P-Purchase | A | Common Stock | 25,000 | 1.16 | 29.0K | 64,848 | — | ↗ |
| 2023-04-17 | TIDMARSH GEORGE F | Director | P-Purchase | A | Common Stock | 26,500 | 1.16 | 30.7K | 39,848 | — | ↗ |
| 2023-04-14 | TIDMARSH GEORGE F | Director | A-Award | A | Stock Option (Right to Buy) | 6,356 | 1.19 | 7.6K | 6,356 | — | ↗ |
| 2023-04-14 | ROPER JESS | Director | A-Award | A | Stock Option (Right to Buy) | 6,356 | 1.19 | 7.6K | 6,356 | — | ↗ |
| 2023-04-14 | LaBelle Curt H | Director | A-Award | A | Stock Option (Right to Buy) | 6,356 | 1.19 | 7.6K | 6,356 | — | ↗ |
| 2023-04-14 | CARVER JENNIFER | Director | A-Award | A | Stock Option (Right to Buy) | 6,356 | 1.19 | 7.6K | 6,356 | — | ↗ |
| 2023-02-25 | Zygmont Chester Stanley III | Officer | A-Award | A | Stock Option (Right to Buy) | 611 | 49.00 | 29.9K | 0 | — | ↗ |
| 2023-02-25 | Rolke James | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,542 | 49.00 | 124.6K | 0 | — | ↗ |
| 2022-12-31 | AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-25 | TIDMARSH GEORGE F | Director / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 1.60 | 32.0K | 467,156 | — | ↗ |
| 2022-02-09 | TIDMARSH GEORGE F | Director / 10% Owner | P-Purchase | A | Common Stock | 30,000 | 2.55 | 76.6K | 447,156 | — | ↗ |
| 2022-02-08 | TIDMARSH GEORGE F | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.54 | 2.5K | 417,156 | — | ↗ |
| 2022-02-07 | TIDMARSH GEORGE F | Director / 10% Owner | P-Purchase | A | Common Stock | 42,100 | 2.61 | 109.8K | 1,523,335 | I | ↗ |
| 2022-02-04 | TIDMARSH GEORGE F | Director / 10% Owner | P-Purchase | A | Common Stock | 7,900 | 2.31 | 18.3K | 1,481,235 | I | ↗ |
| 2022-01-10 | Zygmont Chester Stanley III | Officer | — | D | Restricted Stock Unit | 15,588 | 0.00 | — | 0 | — | ↗ |
| 2022-01-10 | TIDMARSH GEORGE F | Director / 10% Owner | — | D | Restricted Stock Unit | 21,422 | 0.00 | — | 0 | — | ↗ |
| 2022-01-10 | Rolke James | Director / Officer | — | D | Restricted Stock Unit | 65,050 | 0.00 | — | 0 | — | ↗ |
| 2022-01-10 | ROPER JESS | Director | — | D | Restricted Stock Unit | 21,422 | 0.00 | — | 0 | — | ↗ |
| 2022-01-10 | LaBelle Curt H | Director | — | D | Restricted Stock Unit | 21,422 | 0.00 | — | 0 | — | ↗ |
| 2022-01-10 | Feis Lawrence | 10% Owner | J-Other | D | Common Stock | 731,950 | 10.20 | 7.47M | 0 | — | ↗ |
| 2022-01-10 | CARVER JENNIFER | Director | — | D | Restricted Stock Unit | 21,422 | 0.00 | — | 0 | — | ↗ |
| 2021-10-13 | Feis Lawrence | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 746,491 | — | ↗ |
| 2021-09-23 | GLAZER CAPITAL, LLC | 10% Owner | S-Sale | D | Common stock, $0.001 par value per share | 611,541 | 10.08 | 6.16M | 381,106 | — | ↗ |
| 2021-09-22 | GLAZER CAPITAL, LLC | 10% Owner | S-Sale | D | Common stock, $0.001 par value per share | 5 | 10.08 | 50.40 | 992,647 | — | ↗ |
| 2021-09-21 | GLAZER CAPITAL, LLC | 10% Owner | S-Sale | D | Common stock, $0.001 par value per share | 43,000 | 10.08 | 433.4K | 992,652 | — | ↗ |
| 2021-03-11 | Carson William Howard | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2020-12-30 | TYPALDOS ANDREAS | Director / Officer / 10% Owner | J-Other | D | Common Stock | 192,962 | 0.00 | — | 1,769,538 | — | ↗ |
| 2020-12-30 | Fitzpatrick Sean H | Director / Officer / 10% Owner | J-Other | D | Common Stock | 192,962 | 0.00 | — | 1,769,538 | — | ↗ |
| 2020-11-09 | GLAZER CAPITAL, LLC | 10% Owner | S-Sale | D | Units | 5,000 | 10.00 | 50.0K | 1,035,652 | — | ↗ |
| 2020-10-16 | Fitzpatrick Sean H | Director / Officer / 10% Owner | J-Other | A | Redeemable Warrant | 83,446 | 0.00 | — | 3,233,446 | — | ↗ |
| 2020-10-12 | GLAZER CAPITAL, LLC | 10% Owner | S-Sale | D | Units | 20 | 10.00 | 200.00 | 1,040,652 | — | ↗ |
| 2020-10-09 | GLAZER CAPITAL, LLC | 10% Owner | S-Sale | D | Units | 9,328 | 10.00 | 93.3K | 1,040,672 | — | ↗ |
| 2020-10-08 | GLAZER CAPITAL, LLC | 10% Owner | — | I | Units | 0 | 0.00 | — | 1,050,000 | — | ↗ |
| 2020-10-07 | TYPALDOS ANDREAS | Director / Officer / 10% Owner | — | I | Redeemable Warrant | 3,150,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-07 | Nicholson Robert D | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2020-10-07 | Hayes Anthony | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2020-10-07 | Fitzpatrick Sean H | Director / Officer / 10% Owner | — | I | Redeemable Warrant | 3,150,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-07 | Dobkin David | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2020-10-07 | Dennis Barry | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2020-10-07 | Angelides Kimon | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
3.72M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Rolke | Chairman & Chief Executive Officer | 884.6K | male |
| Chester Stanley Zygmont | Chief Financial Officer & Corporate Secretary | 603.8K | male |
| Carol Odle | Senior Director of Clinical Projects | — | female |
| Sandra Vedrick | Vice President of Human Resources & Investor Relations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2019-07-31 | 2019-08-06 | Pat Toomey | PA | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2018-07-27 | 2018-08-03 | Pat Toomey | PA | Self | Sale (Partial) | $15,001 - $50,000 | ↗ |
| 2018-06-25 | 2019-08-12 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-06-06 | 2018-07-18 | Pat Toomey | PA | Self | Sale (Partial) | $15,001 - $50,000 | ↗ |
| 2018-05-16 | 2019-08-12 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-04-30 | 2018-05-15 | Pat Toomey | PA | Self | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-03-22 | 2019-08-12 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-03-22 | 2018-04-10 | Pat Toomey | PA | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2018-02-08 | 2019-08-12 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-02-08 | 2018-03-07 | Pat Toomey | PA | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2018-01-30 | 2019-08-12 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-01-30 | 2018-02-07 | Pat Toomey | PA | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2018-01-08 | 2019-08-12 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-01-08 | 2018-01-10 | Pat Toomey | PA | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2017-12-07 | 2018-05-02 | Pat Toomey | PA | Self | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-12-07 | 2018-01-10 | Pat Toomey | PA | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2017-11-30 | 2018-08-13 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-11-30 | 2017-12-21 | Pat Toomey | PA | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2017-11-17 | 2018-08-13 | Pat Toomey | PA | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-11-17 | 2017-12-21 | Pat Toomey | PA | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for REVB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
